| Evaluation of the Training Program for Community Pharmacists for Dispensing Emicizumab (HEMLIBRA®) in France (NCT05449197) | Hospices Civils de Lyon | 2022-07-01 |
| Validation and Reliability of the CHO-KLAT in Turkish (NCT05439642) | Yuzuncu Yil University | 2022-06-01 |
| Study of Surgical Practices in Patients With Haemophilia A or B Treated With an Extended Half-life Recombinant Factor VIII-Fc or IX-Fc (ELOCTA®, ALPROLIX®) (NCT06158334) | Hospices Civils de Lyon | 2022-06-01 |
| Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor (NCT05487976) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-04-28 |
| UPLC-MS/MS Monitoring of Emicizumab Therapy (NCT04472169) | University Hospital, Lille | 2022-04-13 |
| Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A (NCT05265767) | Christian Medical College, Vellore, India | 2022-04-01 |
| A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood (NCT05147662) | Bayer | 2022-03-23 |
| Intensive Replacement Treatment in Haemophilia Patients With Synovitis (NCT04784988) | Federico II University | 2022-03-01 |
| Emicizumab PUPs and Nuwiq ITI Study (NCT04030052) | Emory University | 2022-02-17 |
| A Study of ADVATE in People With Hemophilia A in India (NCT04985682) | Baxalta now part of Shire | 2022-01-14 |
| A Study in Children, Teenagers and Adults With Severe Hemophilia A Who Switched From Other Factor VIII Treatments to Adynovate (NCT04876365) | Takeda | 2021-11-30 |
| Acquired Hemophilia A and Autoimmunity. Study of Lymphocyte Populations and Myeloid-Derived Suppressor Cells (NCT04805021) | Nantes University Hospital | 2021-11-30 |
| Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors (NCT05145127) | Pfizer | 2021-11-17 |
| Pre-clinical Models for Mesenchymal Stem Cell Therapy in Hemophilic Arthropathy (NCT05187936) | University Hospital, Montpellier | 2021-10-01 |
| A Study of Standard and Individualized Prophylactic Treatment With Advate in Men and Boys With Severe Hemophilia A (NCT04953000) | Takeda | 2021-08-19 |
| Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A (NCT05042440) | Sanofi | 2021-08-11 |
| Outcomes of Prophylaxis With Emicizumab in Children With Severe Hemophilia A in Ivory Coast (NCT05279924) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2021-07-01 |
| A Study of TAK-660 in Surgical Procedures for People With Hemophilia A. (NCT04941898) | Takeda | 2021-06-30 |
| A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection (NCT05251090) | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 2021-06-16 |
| Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study) (NCT04091386) | Bayer | 2021-06-10 |
| Vitamin K Antagonist Versus Direct Oral Anticoagulant Treatments in Hemophilia (NCT05804734) | Groupe Maladies hémorragiques de Bretagne | 2021-06-01 |
| Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST) (NCT04731701) | Swedish Orphan Biovitrum | 2021-05-05 |
| Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A (NCT04845399) | Zhengzhou Gensciences Inc | 2021-04-16 |
| Health Related Quality of Life of Youth and Young Adults With Haemophilia A (NCT04728217) | The League of Clinical Research, Russia | 2021-04-15 |
| POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies (NCT04690322) | University of Texas Southwestern Medical Center | 2021-04-15 |
| Gene Therapy for Chinese Hemophilia A (NCT04728841) | Institute of Hematology & Blood Diseases Hospital, China | 2021-03-04 |
| Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A (NCT04644575) | Bioverativ, a Sanofi company | 2021-02-23 |
| Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A (NCT04759131) | Bioverativ, a Sanofi company | 2021-02-19 |
| Clinical and Health-related Outcome of rFVIIIFc Prophylaxis (NCT04583930) | Prof. Dr. Dr. Thomas Hilberg | 2021-02-01 |
| Medication Adherence and Non-adherence in Adults With Rare Disease (NCT04541875) | Xperiome | 2021-01-01 |
| BT200 in Hereditary Bleeding Disorders (NCT04677803) | Medical University of Vienna | 2020-12-14 |
| Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A (NCT04323098) | BioMarin Pharmaceutical | 2020-12-08 |
| National Longitudinal Cohort of Hematological Diseases (NCT04645199) | Institute of Hematology & Blood Diseases Hospital, China | 2020-12-01 |
| An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A. (NCT04456387) | Zhengzhou Gensciences Inc | 2020-10-15 |
| Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A (NCT04541628) | Eli Lilly and Company | 2020-09-28 |
| A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A (NCT04565236) | Bayer | 2020-09-22 |
| Preventing Inhibitor Recurrence Indefinitely (NCT04621916) | Children's Hospital Los Angeles | 2020-09-21 |
| Pulsed Electromagentic Field in Haemophilia (NCT04590456) | Delta University for Science and Technology | 2020-09-01 |
| A Study to Evaluate Seroprevalence and Seroconversion of Antibodies to Adeno-Associated Virus (AAV) in Patients With Hemophilia A (NCT04560933) | BioMarin Pharmaceutical | 2020-08-25 |
| Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults (NCT04370054) | Pfizer | 2020-08-18 |
| Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A (NCT03818763) | Medical College of Wisconsin | 2020-04-29 |
| A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health (NCT04293523) | Swedish Orphan Biovitrum | 2020-03-30 |
| Treatment of Hemophilia A Patients With FVIII Inhibitors (NCT04023019) | Emory University | 2020-03-17 |
| Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B (NCT03938792) | Pfizer | 2020-03-09 |
| Gaining Insight Into the Complexity of Pain in Patients With Haemophilia (NCT05606640) | Universiteit Antwerpen | 2020-02-13 |
| A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors (NCT04158648) | Hoffmann-La Roche | 2020-02-10 |
| Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A Patients (NCT04396639) | Pfizer | 2020-01-25 |
| Impact on French Physician's Haemophilia Treatment Management Decision Based on Systematic Joint Examination (NCT04133883) | Swedish Orphan Biovitrum | 2020-01-13 |
| PHYSICAL ACTIVITY AND FVIII CLEARANCE: RELEVANCE FOR PERSONALIZED THERAPY IN SEVERE HAEMOPHILIA A (PHYSEMO) (NCT04303936) | Catholic University of the Sacred Heart | 2020-01-09 |
| Physical Activity and FVIII Elimination: Relevance to Personalized Therapy in Severe Hemophilia A (NCT05752565) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2020-01-09 |
| Safety,Efficacy and Pharmacokinetics Evaluation of SCT800 in Previously Treated Paediatric Patients With Severe Haemophilia A. (NCT03947320) | Sinocelltech Ltd. | 2019-12-20 |
| Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A (NCT03932201) | Bayer | 2019-10-21 |
| Handheld Ultrasound (HHUS) for Home Use in Hemophilia (NCT04131920) | Washington Institute for Coagulation | 2019-10-01 |
| Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia (NCT04072237) | Catalyst Biosciences | 2019-09-24 |
| Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation) (NCT04085458) | Bayer | 2019-09-23 |
| Association Between Individual Clotting Factor Level Monitoring and the Risk of Bleeding Whilst Physical Active Conditions (NCT04845555) | Prof. Dr. Dr. Thomas Hilberg | 2019-09-01 |
| Patient-reported Outcomes in Subjects Treated With ReFacto AF Routine Prophylaxis (NCT02718677) | Pfizer | 2019-09-01 |
| The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a and B) (NCT04073498) | ApcinteX Ltd | 2019-08-14 |
| Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII) (NCT04015492) | Bayer | 2019-08-08 |
| Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients. (NCT03947567) | Sinocelltech Ltd. | 2019-07-26 |
| Personalized Medicine for Canadians With Hemophilia (NCT03615053) | McMaster University | 2019-07-24 |
| Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A. (NCT04060836) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-05-08 |
| Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A (NCT04131036) | Washington Institute for Coagulation | 2019-04-04 |
| A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (NCT03747653) | Kaifeng Pharmaceutical (Group) Co., Ltd. | 2019-03-08 |
| Post Marketing Surveillance Study for ADYNOVATE in South Korea (NCT03824522) | Takeda | 2019-02-25 |
| Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants (NCT03876301) | Spark Therapeutics, Inc. | 2019-01-21 |
| Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A (NCT03815318) | Sinocelltech Ltd. | 2019-01-21 |
| Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle" (NCT03588299) | Bayer | 2018-11-07 |
| Early Check: Expanded Screening in Newborns (NCT03655223) | RTI International | 2018-10-15 |
| ATHN 8: Previously Untreated Patients (PUPs) Matter Study (NCT03818529) | American Thrombosis and Hemostasis Network | 2018-10-03 |
| Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders (NCT03834727) | Oregon Health and Science University | 2018-09-05 |
| Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry (NCT03603275) | Bayer | 2018-08-06 |
| Exercise Versus DDAVP in Patients With Mild Hemophilia A (NCT03379974) | Nationwide Children's Hospital | 2018-07-31 |
| A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%) (NCT03587116) | Pfizer | 2018-07-26 |
| Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq (NCT03344003) | Octapharma | 2018-06-28 |
| Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures (NCT03361137) | Genentech, Inc. | 2018-06-28 |
| Web Accessible Population Pharmacokinetics Service - Hemophilia: Sources of Variability (NCT03533504) | McMaster University | 2018-05-09 |
| Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants (NCT03315455) | Hoffmann-La Roche | 2018-04-26 |
| Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5 (NCT03520712) | BioMarin Pharmaceutical | 2018-04-24 |
| Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg (NCT03392974) | BioMarin Pharmaceutical | 2018-03-14 |
| A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers (NCT03380780) | Hoffmann-La Roche | 2018-03-12 |
| A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors (NCT03417245) | Genzyme, a Sanofi Company | 2018-03-01 |
| A Study of BAX 888 in Male Adults With Severe Hemophilia A (NCT03370172) | Baxalta now part of Shire | 2018-02-27 |
| A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors (NCT03417102) | Genzyme, a Sanofi Company | 2018-02-14 |
| Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies (NCT03405337) | Bayer | 2018-02-14 |
| World Bleeding Disorders Registry (NCT03327779) | World Federation of Hemophilia | 2018-01-26 |
| Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301) (NCT03370913) | BioMarin Pharmaceutical | 2017-12-19 |
| BAY94-9027 PK Study Comparing to Another Long Acting Product (NCT03364998) | Bayer | 2017-11-30 |
| A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors (NCT03191799) | Hoffmann-La Roche | 2017-09-05 |
| Understanding Hemophilia A and B Drug Dosage Administration Patterns (NCT03248141) | Pfizer | 2017-09-01 |
| Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies (NCT03103542) | Swedish Orphan Biovitrum | 2017-08-29 |
| A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A) (NCT03205163) | Bioverativ, a Sanofi company | 2017-08-28 |
| A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A (NCT03061201) | Pfizer | 2017-06-21 |
| Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A (NCT02971930) | Bayer | 2017-06-20 |
| Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia (NCT03185897) | Baxalta now part of Shire | 2017-06-14 |
| INdividualized ITI Based on Fviii(ATE) Protection by VWF (NCT03204539) | University of California, Davis | 2017-06-01 |
| Data Registry in Chinese Hemophilia A and B Patients (NCT07101224) | Institute of Hematology & Blood Diseases Hospital, China | 2017-05-07 |
| Evaluation of a Standardized Protocol for Thrombin Generation Assay (NCT03313531) | Lund University | 2017-04-15 |
| ADYNOVATE Drug Use-Results Survey (NCT03169972) | Takeda | 2017-02-01 |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A (NCT03020160) | Hoffmann-La Roche | 2017-01-30 |